Efficacy and safety of 5-aminolevulinic acid in adult-onset Still's disease A preclinical study in mice and a pilot study in humans

Efficacy and safety of 5-aminolevulinic acid in adult-onset Still's disease : A preclinical study in mice and a pilot study in humans

Copyright © 2023. Published by Elsevier Inc.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 257(2023) vom: 15. Dez., Seite 109846
1. Verfasser: Koga, Tomohiro (VerfasserIn)
Weitere Verfasser: Sumiyoshi, Remi, Tsuji, Yoshika, Kodama, Ken, Endo, Yushiro, Furukawa, Kaori, Kawakami, Atsushi
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2023
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't 5-aminolevulinic acid/sodium ferrous citrate Adult-onset Still's disease Collagen-induced arthritis Macrophage activation syndrome Aminolevulinic Acid 88755TAZ87
Beschreibung
Zusammenfassung:Copyright © 2023. Published by Elsevier Inc.
The study aimed to investigate the therapeutic effects of 5-aminolevulinic acid/sodium ferrous citrate (5-ALA/SFC) on adult-onset Still's disease (AOSD), specifically focusing on arthritis and macrophage activation syndrome (MAS). We used mouse models to assess the impact of 5-ALA/SFC on collagen-induced arthritis (CIA) and MAS induced by synthetic oligonucleotides containing CpG motifs (CpG-S-ODN). Additionally, we conducted a pilot study with AOSD patients receiving prednisolone (PSL) treatment and 5-ALA/SFC administration to evaluate its efficacy and safety. The 5-ALA/SFC group exhibited significantly lower joint scores in CIA mice. In CpG-S-ODN-treated mice, 5-ALA/SFC administration led to reduced hemophagocytosis and splenomegaly. The anti-inflammatory properties of 5-ALA/SFC were attributed to the suppression of CCL4 and CXCL10 production in monocytes and the induction of M2 macrophages. AOSD patients treated with 5-ALA/SFC demonstrated successful PSL tapering without adverse events. Collectively, the administration of 5-ALA/SFC showed promising potential in ameliorating arthritis and MAS in AOSD patients
Beschreibung:Date Completed 16.12.2023
Date Revised 10.04.2024
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2023.109846